Disease · EFO_0007425

peanut allergic reaction

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. peanut allergic reaction. Diseases, record EFO_0007425. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0007425

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: peanut allergic reaction; Open Targets
Open Targets ID: EFO_0007425; Open Targets
Other names: Allergy to peanuts (disorder), Peanut Hypersensitivity, Peanut allergy; Open Targets
Disease Ontology: DOID:4378; Disease Ontology
MeSH: D021183; MeSH
Highest stage of its drugs: Approval, for 1 of its 13 drugs, from EMA Human Drugs; Open Targets

Drugs13

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DEFATTED POWDER OF ARACHIS HYPOGAEA L., SEMEN (PEANUTS)	CHEMBL5315089		Approval	EMA Human Drugs	23	22	14	Drugs and targets
OMALIZUMAB	CHEMBL1201589	Antibody	Phase 3	ClinicalTrials.gov	11	11	11	Drugs and targets
KBPA-101	CHEMBL2109535		Phase 3	ClinicalTrials.gov	9	9	9	Drugs and targets
LIGELIZUMAB	CHEMBL2109457	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
DUPILUMAB	CHEMBL2108675	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
OATMEAL, COLLOIDAL	CHEMBL2109173		Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
VANCOMYCIN	CHEMBL262777	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ETOKIMAB	CHEMBL4297580	Antibody	Phase 2	ClinicalTrials.gov	2	1	1	Drugs and targets
ABATACEPT	CHEMBL1201823	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DESLORATADINE	CHEMBL1172	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 13

See all 13 drugs

Targets7

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
IGHE	Immunoglobulin heavy constant epsilon	2	Ig epsilon chain C region inhibitor	Phase 3	https://conductscience.org/library/genes/3497	Drugs and targets
CD80	T-lymphocyte activation antigen CD80	1	T-lymphocyte activation antigen CD80 inhibitor	Phase 2	https://conductscience.org/library/genes/941	Drugs and targets
CD86	T-lymphocyte activation antigen CD86	1	T-lymphocyte activation antigen CD86 inhibitor	Phase 2	https://conductscience.org/library/genes/942	Drugs and targets
HRH1	Histamine H1 receptor	1	Histamine H1 receptor antagonist	Phase 2	https://conductscience.org/library/genes/3269	Drugs and targets
IL33	Interleukin-33	1	Interleukin-33 binding agent	Phase 2	https://conductscience.org/library/genes/90865	Drugs and targets
IL4R	Interleukin-4 receptor subunit alpha	1	Interleukin-4 receptor subunit alpha antagonist	Phase 2	https://conductscience.org/library/genes/3566	Drugs and targets
TSLP	Thymic stromal lymphopoietin	1	Thymic stromal lymphopoietin inhibitor	Phase 2	https://conductscience.org/library/genes/85480	Drugs and targets

Trials45

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 8 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03292484	Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)	Phase 3	911	2024-12-19	Peanut Allergy	KBPA-101	Its record names the disease	ClinicalTrials.gov
NCT02635776	Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)	Phase 3	555	2022-03-17	Peanut Allergy	KBPA-101	Its record names the disease	ClinicalTrials.gov
NCT03126227	Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES)	Phase 3	506	2021-11-02	Peanut Allergy	KBPA-101	Its record names the disease	ClinicalTrials.gov
NCT02636699	Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy	Phase 3	500	2021-10-15	Peanut Allergy	DEFATTED POWDER OF ARACHIS HYPOGAEA L., SEMEN (PEANUTS)	Its record names the disease	ClinicalTrials.gov
NCT03881696	Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants	Phase 3	458	2024-06-04	Peanut Allergy, Multi-food Allergy	OMALIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03211247	Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age	Phase 3	414	2024-12-16	Peanut Allergy	DEFATTED POWDER OF ARACHIS HYPOGAEA L., SEMEN (PEANUTS)	Its record names the disease	ClinicalTrials.gov
NCT02993107	PALISADE Follow-on Study (ARC004)	Phase 3	388	2021-12-15	Peanut Allergy	KBPA-101	Its record names the disease	ClinicalTrials.gov
NCT03337542	AR101 Real-World Open-Label Extension Study	Phase 3	243	2021-11-02	Peanut Allergy	KBPA-101	Its record names the disease	ClinicalTrials.gov
NCT01675882	Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy	Phase 2	221	2021-10-27	Peanut Allergy	DEFATTED POWDER OF ARACHIS HYPOGAEA L., SEMEN (PEANUTS)	Its record names the disease	ClinicalTrials.gov
NCT04984876	Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy	Phase 3	211	2024-10-08	Allergy, Peanut	LIGELIZUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 45

See all 45 trials

Comparisons in its trials47

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
AR101 Powder Provided in Capsules vs Placebo Powder: Frequency of Epinephrine Use as Rescue Medication	37 of 337	9 of 168	505	NCT03126227	Trial comparisons
AR101 Powder Provided in Capsules vs Placebo Powder: Frequency of Accidental Ingestion of Peanut and Other Allergenic Foods	26 of 337	31 of 168	505	NCT03126227	Trial comparisons
AR101 Powder Provided in Capsules vs Placebo Powder: Frequency of Adverse Events That Led to Early Withdrawal	36 of 337	5 of 168	505	NCT03126227	Trial comparisons
AR101 Powder Provided in Capsules vs Placebo Powder: Frequency of Premature Discontinuation of Dosing Due to Adverse Events	41 of 337	5 of 168	505	NCT03126227	Trial comparisons
AR101 Powder Provided in Capsules vs Placebo Powder: Frequency of Anaphylaxis as Defined in the Protocol	36 of 337	9 of 168	505	NCT03126227	Trial comparisons
AR101 Powder Provided in Capsules vs Placebo Powder: Frequency of Premature Discontinuation of Dosing Due to Chronic/Recurrent Gastrointestinal Adverse Events	20 of 337	0 of 168	505	NCT03126227	Trial comparisons
AR101 Powder Provided in Capsules vs Placebo Powder: deaths from any cause	0 of 337	1 of 168	505	NCT03126227	Trial comparisons
AR101 Powder Provided in Capsules vs Placebo Powder: serious adverse events	2 of 337	2 of 168	505	NCT03126227	Trial comparisons
AR101 vs Placebo: Percentage of Subjects Ages 4-17 Who Tolerated a Single Highest Dose of at Least 1000 mg in the Exit Double-Blind, Placebo-Controlled Food Challenge (DBPCFC)	187 of 372	3 of 124	496	NCT02635776	Trial comparisons
AR101 vs Placebo: Percentage of Subjects Ages 4-17 Who Tolerated a Single Highest Dose of at Least 600 mg in the Exit Double-Blind, Placebo-Controlled Food Challenge (DBPCFC)	250 of 372	5 of 124	496	NCT02635776	Trial comparisons

1 to 10 of 47

See all 47 comparisons in its trials

Papers from its trials42

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38407394	RESULT	1	PubMed
37087097	RESULT	1	PubMed
35014049	RESULT	1	PubMed
32502548	RESULT	1	PubMed
31723064	RESULT	1	PubMed
30794314	RESULT	1	PubMed
28091362	RESULT	1	PubMed
42685867	DERIVED	1	PubMed
41651410	DERIVED	1	PubMed
41615410	DERIVED	2	PubMed

1 to 10 of 42

See all 42 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0007425

GET https://conductscience.org/api/diseases/v1/EFO_0007425/trials?page=2

API reference For AI assistants